FDA approves new treatment for patients with migraine - FDA Press Releases

The U.S. Food and Drug Administration today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated for the preventive treatment of migraine.

from FDA Press Releases RSS Feed https://ift.tt/325Nxji
via IFTTT